PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21368751-3	2011	We have shown in vitro that ezetimibe and tacrolimus may interact in competition for intestinal UGT1A1 and ABCB1 at concentrations reached in gut lumen after oral administration.	Ezetimibe	28-37	ATP binding cassette subfamily B member 1	Homo sapiens	107-112	
20220747-1	2010	Organ transplant recipients who have dyslipidemia related to immunosuppression may benefit from cholesterol-lowering therapy with ezetimibe, a substrate of ABCB1, ABCC2, and OATP1B1.	Ezetimibe	130-139	ATP binding cassette subfamily B member 1	Homo sapiens	156-161	
20220747-3	2010	However, competition between sirolimus and ezetimibe for ABCB1 and OATP1B1 is not of major clinical relevance, as confirmed in our randomized, controlled, single-dose study in healthy subjects.	Ezetimibe	43-52	ATP binding cassette subfamily B member 1	Homo sapiens	57-62	
17828742-1	2007	The lipid lowering agent ezetimibe (EZ) and its intestinally formed glucuronide (GLUC) were shown to be substrates of the efflux transporters P-glycoprotein (P-gp) and the multidrug resistance associated protein 2 (MRP2) which markedly influences the disposition and efficacy of EZ in man.	Ezetimibe	25-34	ATP binding cassette subfamily B member 1	Homo sapiens	142-156	
17828742-1	2007	The lipid lowering agent ezetimibe (EZ) and its intestinally formed glucuronide (GLUC) were shown to be substrates of the efflux transporters P-glycoprotein (P-gp) and the multidrug resistance associated protein 2 (MRP2) which markedly influences the disposition and efficacy of EZ in man.	Ezetimibe	25-34	ATP binding cassette subfamily B member 1	Homo sapiens	158-162	
17828742-1	2007	The lipid lowering agent ezetimibe (EZ) and its intestinally formed glucuronide (GLUC) were shown to be substrates of the efflux transporters P-glycoprotein (P-gp) and the multidrug resistance associated protein 2 (MRP2) which markedly influences the disposition and efficacy of EZ in man.	Ezetimibe	36-38	ATP binding cassette subfamily B member 1	Homo sapiens	142-156	
17828742-1	2007	The lipid lowering agent ezetimibe (EZ) and its intestinally formed glucuronide (GLUC) were shown to be substrates of the efflux transporters P-glycoprotein (P-gp) and the multidrug resistance associated protein 2 (MRP2) which markedly influences the disposition and efficacy of EZ in man.	Ezetimibe	36-38	ATP binding cassette subfamily B member 1	Homo sapiens	158-162	
16513445-0	2006	Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans.	Ezetimibe	243-252	ATP binding cassette subfamily B member 1	Homo sapiens	25-39	
16513445-8	2006	Intestinal expression of UGT1A1, ABCB1, and ABCC2 was inversely correlated with the effects of ezetimibe on plant sterol serum concentrations.	Ezetimibe	95-104	ATP binding cassette subfamily B member 1	Homo sapiens	33-38	
16513445-0	2006	Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans.	Ezetimibe	243-252	ATP binding cassette subfamily B member 1	Homo sapiens	41-46	
16513445-9	2006	Parallel in vitro studies confirmed that ezetimibe glucuronide is a high-affinity substrate of MRP2 and has a low affinity to P-gp whereas ezetimibe interacts with P-gp and MRP2.	Ezetimibe	41-50	ATP binding cassette subfamily B member 1	Homo sapiens	126-130	
16513445-6	2006	The affinity of ezetimibe and its glucuronide to P-gp and MRP2 was assessed in P-gp- overexpressing Madin-Darby canine kidney II cells and P-gp-containing or MRP2-containing inside-out vesicles.	Ezetimibe	16-25	ATP binding cassette subfamily B member 1	Homo sapiens	79-83	
16513445-10	2006	CONCLUSIONS: The disposition and sterol-lowering effects of ezetimibe are modified by metabolic degradation of the drug via intestinal UGT1A1 and either intestinal or hepatic secretion (or both) via P-gp and MRP2.	Ezetimibe	60-69	ATP binding cassette subfamily B member 1	Homo sapiens	199-203	
16513445-6	2006	The affinity of ezetimibe and its glucuronide to P-gp and MRP2 was assessed in P-gp- overexpressing Madin-Darby canine kidney II cells and P-gp-containing or MRP2-containing inside-out vesicles.	Ezetimibe	16-25	ATP binding cassette subfamily B member 1	Homo sapiens	79-83